Athersys Overview

  • Founded
  • 1995
Founded
  • Status
  • Public
  • Employees
  • 104
Employees
  • Stock Symbol
  • ATHX
Stock Symbol
  • Investments
  • 1
  • Share Price
  • $0.65
  • (As of Monday Closing)

Athersys General Information

Description

Athersys Inc is a biotechnology company. It is focused on developing novel and proprietary therapies in the areas where there is an unmet medical need, particularly in the regenerative medicine area. The firm's main product is Multistem cell therapy. Its current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders and certain pulmonary conditions. Its revenue has been derived from corporate collaborations, license agreements, and government grants.

Contact Information

Ownership Status
Publicly Held
Financing Status
Corporate Backed or Acquired
Primary Industry
Pharmaceuticals
Other Industries
Biotechnology
Stock Exchange
NAS
Primary Office
  • 3201 Carnegie Avenue
  • Cleveland, OH 44115
  • United States
+1 (216) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Athersys Stock Performance

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.65 $0.58 $0.46 - $1.81 $147M 258M 2.91M -$0.35

Athersys Financials Summary

In Thousands,
USD
TTM 31-Mar-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 120,089 172,231 284,263 152,254
Revenue 8,426 5,514 1,432 5,517
EBITDA (81,273) (85,528) (77,875) (43,884)
Net Income (82,703) (86,955) (78,765) (44,582)
Total Assets 44,959 60,184 59,714 41,666
Total Debt 9,519 9,766 677
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Athersys Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Athersys‘s full profile, request access.

Request a free trial

Athersys Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Athersys Inc is a biotechnology company. It is focused on developing novel and proprietary therapies in the areas where
Pharmaceuticals
Cleveland, OH
104 As of 2021
0000
000000000 0000

0000000

dunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco la
0000 000000000
San Diego, CA
000 As of 0000
00000
0000 0000-00-00
00000000000 00000

0000000

o laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in volupta
0000000000000
Ann Arbor, MI
000 As of 0000
00000
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Athersys Competitors (40)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
ViaCyte Venture Capital-Backed San Diego, CA 000 00000 00000000000 00000
0000000 Corporation Ann Arbor, MI 000 00000 00000000 00000
0000000 Corporation Gaithersburg, MD 0000 00000 000000000 00000
0000000000 Corporate Backed or Acquired Basel, Switzerland 000000&0
0000000000 0000000 Formerly VC-backed San Diego, CA 000 00000 000000&0
You’re viewing 5 of 40 competitors. Get the full list »

Athersys Patents

Athersys Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20200363116-A1 Apparatus and method for cryostorage and manipulation of a plurality of container units Pending 13-May-2019 000000000
CA-3127793-A1 Multipotent adult progenitor cells for use in treating intracerebral hemorrhage Pending 01-Feb-2019 000000000
AU-2020216403-A1 Multipotent adult progenitor cells for use in treating intracerebral hemorrhage Pending 01-Feb-2019 000000000
EP-3917545-A1 Multipotent adult progenitor cells for use in treating intracerebral hemorrhage Pending 01-Feb-2019 000000000
US-20200246390-A1 Multipotent adult projenitor cells for treatment of ich Pending 01-Feb-2019 A61K35/12
To view Athersys’s complete patent history, request access »

Athersys Executive Team (12)

Name Title Board Seat Contact Info
Daniel Camardo Chief Executive Officer & Board Member
William Lehmann Jr. Chief Operating Officer and President
Ivor Macleod Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
John Harrington Ph.D Co-Founder, Board Member, Executive Vice President and Chief Scientific Officer
Karen Hunady Director of Corporate Communications and Investor Relations
You’re viewing 5 of 12 executive team members. Get the full list »

Athersys Board Members (16)

Name Representing Role Since
00000 0000 00 Self Board Member 000 0000
000000 0000000 Athersys Chief Executive Officer & Board Member 000 0000
00000 00000000 Self Board Member 000 0000
000000 0000 00.0 Self Chairman & Board Member 000 0000
0000 000000000000 Self Board Member 000 0000
You’re viewing 5 of 16 board members. Get the full list »

Athersys Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Athersys Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Athersys‘s full profile, request access.

Request a free trial

Athersys Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000 00 08-Jun-2007 0000000000 Special Purpose Acquisition Company (SPAC)
To view Athersys’s complete acquisitions history, request access »